Imagine you are the Quality Director of a site manufacturing critical medicinal products or medical devices. You have a sickness absence rate of 50% of QA and QC staff. What do you do?
Why becoming more risk literate is so vital
A substantial number of cell and gene therapies (C>s) delivering a cure or at least durable health benefits are expected over the next 5 to 10 years – for example, MIT NEWDIGS researchers estimated that about 40 gene therapies may be approved by the end of 2022.
Organizational change can take on many guises. Most changes are planned and orchestrated by company management. However, some of the most impactful changes are nearly impossible to predict.